![]() |
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
Sponsored by: |
Novartis |
---|---|
Information provided by: | Novartis |
ClinicalTrials.gov Identifier: | NCT00232076 |
To assess the efficacy and safety of oral OL27-400MEPC 3 mg/kg/day (2-5 mg/kg/day) in 2 divided doses daily for 8 weeks to patients with severe adult atopic dermatitis.
THIS STUDY IS NOT ENROLLING PATIENTS IN THE UNITED STATES
Condition | Intervention | Phase |
---|---|---|
Severe Atopic Dermatitis |
Drug: ciclosporin |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Single Group Assignment, Safety/Efficacy Study |
Official Title: | Verification Study of Ciclosporin for Atopic Dermatitis |
Ages Eligible for Study: | 20 Years to 64 Years |
Genders Eligible for Study: | Both |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | COLO400D1303 |
Study First Received: | October 3, 2005 |
Last Updated: | October 10, 2005 |
ClinicalTrials.gov Identifier: | NCT00232076 |
Health Authority: | Japan: Ministry of Health, Labor and Welfare |
Atopic Dermatitis, Ciclosporin, |
Dermatitis, Atopic Cyclosporine Skin Diseases Clotrimazole Miconazole Tioconazole Cyclosporins |
Hypersensitivity Genetic Diseases, Inborn Hypersensitivity, Immediate Skin Diseases, Eczematous Skin Diseases, Genetic Dermatitis |
Anti-Infective Agents Immunologic Factors Molecular Mechanisms of Pharmacological Action Immune System Diseases Therapeutic Uses Antifungal Agents |
Physiological Effects of Drugs Enzyme Inhibitors Antirheumatic Agents Dermatologic Agents Immunosuppressive Agents Pharmacologic Actions |